This ASX 200 healthcare stock is up 48% in a year, but one director is still buying!

A director of this ASX 200 healthcare company has just lifted his personal stake by 50%.

| More on:
Health workers shake hands and congratulate each other on good news.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX 200 healthcare stock Neuren Pharmaceuticals Ltd (ASX: NEU) has posted impressive gains over the past year but one director appears to still see value in today's share price.

Neuren shares closed the session on Thursday at $19.31, up 2.6% for the day. The ASX 200 healthcare stock outperformed the benchmark S&P/ASX 200 Index (ASX: XJO), which rose by 0.44%.

Over the past year, the Neuren Pharmaceuticals share price has risen 48.3% while the ASX 200 has lifted just 8.6%.

So, it's interesting to see one of the company directors ploughing more of his own funds into the ASX 200 healthcare stock despite this impressive price lift.

Director invests almost $100,000 in Neuren shares

Neuren Pharmaceuticals issued a notice to the ASX yesterday advising that director Joseph Basile has increased his stake in the company by 50%.

Basile bought 5,000 Neuren shares on-market on Tuesday through his self-managed super fund (SMSF) for $19.49 apiece, for a total consideration of $97,450.

He already owned 10,000 Neuren shares, so the purchase lifted his stake in the ASX 200 healthcare stock by 50%.

What's the latest news from this ASX 200 healthcare stock?

The last piece of price-sensitive news from Neuren came on 27 May when the company announced top-line results from the Phase 2 clinical trial of its second drug candidate, NNZ-2591.

The drug treats Pitt Hopkins syndrome (PTHS), which is a neurodevelopmental condition that causes developmental delays. It causes moderate to severe intellectual disability, hyperventilation and/or breath-holding while awake, seizures, gastrointestinal issues, speech difficulties, and sleep disturbances.

The top-line results showed a "statistically significant improvement" across all four efficacy measures.

Neuren Pharmaceuticals CEO Jon Pilcher said:

We are very excited about the results of this first clinical trial in Pitt Hopkins patients. This underserved community has such urgent unmet need and we can now continue towards our goal of developing a first approved treatment.

The ASX 200 healthcare stock rocketed 15.7% on the day of the news.

PTHS is caused by the loss of one copy, or a mutation, of the TCF4 gene on the 18th human chromosome. The incidence of PTHS is estimated at between 1 in 11,000 people and 1 in 41,000 people.

Neuren develops drugs for serious childhood neurological disorders that have no or limited approved treatments.

In the United States, all of its drugs have the designation of 'orphan drug'. Biotechs working on orphan drugs are given special incentives, such as longer exclusive marketing rights, to ensure they make a profit.

Neuren also has an orphan drug designation for NNZ-2591 in Europe.

Neuren Pharmaceuticals share price snapshot

This ASX 200 healthcare stock has flown 1,565% higher over the past five years.

This compares to an 18.3% gain for the ASX 200.

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

Telix Pharmaceuticals share price sinks on unexpected Nasdaq news

ASX 200 investors are bidding down the Telix Pharmaceuticals share price today. But why?

Read more »

A man and woman in an office look at a laptop and discuss investing, budget strategies or other financial concepts
Healthcare Shares

Why this broker just upgraded Telix shares to a buy rating

Bell Potter thinks a recent pullback has created a buying opportunity.

Read more »

A female scientist sits at her desk looking stressed out while working in an AnteoTech lab.
Healthcare Shares

Sigma share price dives 6% on Chemist Warehouse merger hurdle

The proposed merger faces ACCC concerns.

Read more »

A person wrapped in warm clothing with head, eyes and face covered by a hat, glasses and a scarf is coated in a layer of snow and ice. representing Strike Energy's trading halt today
Healthcare Shares

Why is the Telix Pharmaceuticals share price frozen today?

Telix Pharmaceuticals shares won’t be moving today.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

3 ASX 300 healthcare stocks 'well positioned to outperform'

Wilsons thinks the healthcare sector could be about to outperform the broader market.

Read more »

A woman researcher holds a finger up in happiness as if making the 'number one' sign with a graphic of technological data and an orb emanating from her finger while fellow researchers work in the background.
Healthcare Shares

CSL shares can 'absolutely' head to $500: ASX expert

This expert reckons it's foolish to bet against CSL...

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

2 ASX biotech shares that could be the next Telix Pharmaceuticals

These ASX biotech shares could become the next Telix Pharmaceuticals. But how?

Read more »

Businessman working on street in New York. Dressing in blue suit, a young guy with beard, sitting outside office building, looking down, reading, typing on laptop computer.
Healthcare Shares

Telix Pharmaceuticals share price jumps to record high on Nasdaq IPO launch

This radiopharmaceuticals company is expecting to pull in US$200m from the move.

Read more »